Literature DB >> 6245789

Expression of A and B tissue isoantigens in benign and malignant lesions of the breast.

J A Strauchen, S M Bergman, T A Hanson.   

Abstract

AB isoantigens are widely distributed in human tissues and loss of AB isoantigen expression has been shown to be an early marker for carcinomatous transformation in some tissues. We therefore applied the Specific Red Cell Adherence Reaction (SRCA) for detection and localization of AB isoantigens in tissue to the study of benign and malignant proliferative lesions of the breast. Twenty-nine lesions in 19 patients were studied. AB isoantigen expression in normal breast tissue was found to be largely confined to the mammary duct system. Loss of AB isoantigen expression was a consistent feature of intraductal carcinoma (3 of 3 cases). Proliferative lesions associated with fibrocystic disease also demonstrated varying degrees of isoantigen loss (simple cystic disease, 3 of 8 cases; intraductal hyperplasia, 6 of 7 cases; sclerosing adenosis, 4 of 4 cases; and intraductal papillomatosis, 7 of 7 cases negative for isoantigen). In contrast to other systems, loss of AB isoantigen expression in the breast appears to be a consistent marker of apparently benign proliferative duct lesions associated with fibrocystic disease, as well as duct carcinoma. The early loss of AB isoantigen expression in these histologically benign lesions supports a possible link between fibrocystic disease and mammary carcinoma. In contrast to other tissues, loss of AB isoantigen expression in proliferative breast lesions is not necessarily evidence of malignancy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245789     DOI: 10.1002/1097-0142(19800415)45:8<2149::aid-cncr2820450823>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  ABO blood group and breast cancer incidence and survival.

Authors:  Margaret A Gates; Mousheng Xu; Wendy Y Chen; Peter Kraft; Susan E Hankinson; Brian M Wolpin
Journal:  Int J Cancer       Date:  2012-02-10       Impact factor: 7.396

2.  Expression of the gene encoding secretor type galactoside 2 α fucosyltransferase (FUT2) and ABH antigens in patients with oral lesions.

Authors:  Carlos Campi; Livia Escovich; Alejandra Moreno; Liliana Racca; Amelia Racca; Carlos Cotorruelo; Claudia Biondi
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-01-01

3.  Prognostic value of ABO blood group in patients with surgically resected colon cancer.

Authors:  X Cao; Z-S Wen; Y-J Sun; Y Li; L Zhang; Y-J Han
Journal:  Br J Cancer       Date:  2014-06-05       Impact factor: 7.640

4.  ABO blood group is a predictor of survival in patients with laryngeal cancer.

Authors:  Ting Jin; Pei-Jing Li; Xiao-Zhong Chen; Wei-Han Hu
Journal:  Chin J Cancer       Date:  2016-10-13

5.  Association of ABO Blood Types and Clinicopathological Features of Prostate Cancer.

Authors:  Fang-Ming Wang; Yan Zhang; Gui-Ming Zhang; Ya-Nan Liu; Li-Jiang Sun; Yong Liu
Journal:  Dis Markers       Date:  2017-10-09       Impact factor: 3.434

6.  ABO blood classification and the risk of lung cancer: A meta-analysis and trial sequential analysis.

Authors:  Haotian Yang; Ziqi Tan; Yizhen Zhang; Jiaqi Sun; Peng Huang
Journal:  Oncol Lett       Date:  2022-08-12       Impact factor: 3.111

7.  The expression of ABH and Y blood group antigens in benign and malignant breast tissue: the preservation of the H and Y antigens in malignant epithelium.

Authors:  P Vowden; A D Lowe; E S Lennox; N M Bleehen
Journal:  Br J Cancer       Date:  1986-03       Impact factor: 7.640

8.  Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer: a retrospective analysis of 1601 cases at a single cancer center.

Authors:  Ning Li; Miao Xu; Chao-Feng Li; Wei Ou; Bao-Xiao Wang; Song-Liang Zhang; Peng-Fei Xu; Cheng Yuan; Qun-Ai Huang; Si-Yu Wang
Journal:  Chin J Cancer       Date:  2015-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.